Prospective, Non-Controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients with Mild to Moderate Pneumonia

The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in December 2019, and has since spread worldwide.The novel coronavirus is now referred to as severe and critical acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) [1].SARS-CoV-2 is transmitted through the respiratory tract and could induce pneumonia [2,3].Bacterial co-infection in the setting of viral pneumonia is known as major cause of mortality [4].Nowadays, there is only conditional marketing authorisation in the European Union for Remdesivir, an antiviral with limited effect in the natural course of pneumonia [5].Taking into account that global vaccination is a medium-term option among the possible strategies, the so-called "repositioning", that is, the use against SARS-CoV-2 of drugs that are already approved to treat other diseases, is established.In consequence, there is a need to evaluate existing drugs with potential efficacy for COVID-19 through clinical trials [6]. Cefditoren (CDN) is a third-generation cephalosporin for oral